Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
-PH-762 is Phio’s lead product candidate-Screening on the next cohort is on-goingMARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio...